Zelboraf (Vemurafenib) Patent Expiration, LOE Window & CMS Spending

Zelboraf (Vemurafenib) by Roche / Genentech: FDA Orange Book core substance LOE 2030-07-27 (last listed 2032-06-06), 0 AB generics, $15.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRoche / Genentech
FDA Application & PathwayN202429 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-07-27
Last Listed Patent or Exclusivity Date2032-06-06
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$15.8M
2024 Medicare Part D Spend$13.4M
2024 Medicaid Spend$2.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.